Showing 7501-7510 of 8720 results for "".
- Illuminate PRP Adds Industry Veteran Redmond as CCOhttps://practicaldermatology.com/news/illuminate-prp-adds-industry-veteran-redmond-cco/2470885/Industry veteran Jennifer Redmond, MBA, joined Illuminate PRP as Chief Commercial Officer, the company announced. “Jennifer brings a wealth of experience in sales and marketing within the aesthetics and pharmaceutical industries, along with strong leadership and a commitment to driving pos
- Review Examines Potential of AI Tools for Physician Burnouthttps://practicaldermatology.com/news/streamlining-charting-ai-tools/2470864/Patient documentation tools powered by AI have the potential to alleviate burnout among dermatologists by streamlining administrative tasks, according to a recent review published in the Journal of Drugs in Dermatology. "The prevalence of burnout among United States (US) dermatolo
- Study IDs Proteins Associated With Inflammatory Mechanisms of Psoriasishttps://practicaldermatology.com/news/study-ids-proteins-associated-inflammatory-mechanisms-psoriasis/2470870/A comparative analysis of dermal mesenchymal stem cell exosomes from healthy human skin and psoriatic lesions revealed 13 differential proteins, according a research published in Current Molecular Medicine. Researchers at Shanxi Medical University published “Proteomic Analysis of Mesenchym
- Analysis: Fibrosis Mechanisms in Systemic Sclerosis Skinhttps://practicaldermatology.com/news/fibrosis-mechanisms-ssc-skin/2470860/Researchers have identified a shift toward reticular gene expression in systemic sclerosis (SSc) skin, with disruptions in WNT/β-catenin signaling playing a key role in these changes. Authors for the study, published in Arthritis and Rheumatology, analyzed skin morphology and mole
- Study: Dual-Action Topical Treatment Reduces Lesion Counts in Adult Acne Patientshttps://practicaldermatology.com/news/study-dual-action-topical-treatment-reduces-lesion-counts-adult-acne-patients/2470855/Results from a recent pilot study suggested that a combination therapy of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel with clascoterone 1% cream was effective in reducing lesions in adult acne patients. Researchers for the study enrolled 20 adult participants with
- Genetic Study Reveals Psoriasis-Sudden Hearing Loss Connectionhttps://practicaldermatology.com/news/genetic-study-reveals-psoriasis-hearing-loss-connection/2470853/A recent genetic study has established a causal relationship between psoriasis and an elevated risk of sudden sensorineural hearing loss (SSNHL). Researchers derived the findings using Mendelian randomization (MR) analysis to identify potential connections between inflammatory skin disease
- Knight Dermatology Institute Partners With Forefront Dermatologyhttps://practicaldermatology.com/news/knight-dermatology-institute-partners-forefront-dermatology/2470808/Knight Dermatology Institute (KDI) and Forefront Dermatology have formed a partnership, Physician Growth Partners (PGP) announced in a press release. Based in Orlando, Florida, KDI is a medically and surgically driven practice with a core focus on skin cancer detection, prevention, and tre
- Method Review: A Closer Look at Cryo-EM’s Impact on Dermatologyhttps://practicaldermatology.com/news/method-review-a-closer-look-at-cryo-ems-impact-on-dermatology/2470806/A recent method review in the Journal of Investigative Dermatology points to the potential of cryogenic electron microscopy (cryo-EM) in dermatological research. According to the authors, advanced imaging technology enables atomic-resolution visualization of macromolecules in thei
- Report: Regenerative Aesthetics Exosome Market Poised for Growth Through 2031https://practicaldermatology.com/news/report-regenerative-aesthetics-exosome-market-poised-355-cagr-through-2031/2470805/The global regenerative aesthetics exosome products market is projected to experience a compound annual growth rate (CAGR) of 35.5% from 2024 to 2031, according to a report from InsightAce Analytic. Exosome-based therapies with applications in skin rejuvenation, hair restoration, scar redu
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov